Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | CKS1B | P61024 | 1/20 | 0.44 |
| ▸ | SKP1 | P63208 | 1/20 | 0.44 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3997637 | 1.00 | PIK3CA (0.53) | PIK3CASMN1; SMN2USP2GBA1MTOR | |
| SCHEMBL29434915 | 1.00 | PIK3CA (0.53) | PIK3CASMN1; SMN2USP2GBA1MTOR | |
| SCHEMBL30162245 | 0.93 | CKS1B (0.49) | PIK3CAGBA1KMT2AMAPTMEN1 | |
| SCHEMBL24851452 | 0.93 | CKS1B (0.49) | PIK3CAGBA1KMT2AMAPTMEN1 | |
| SCHEMBL18153359 | 0.90 | GBA1 (0.51) | GBA1KMT2AMEN1CKS1BSKP1 | |
| SCHEMBL24851765 | 0.90 | GBA1 (0.51) | GBA1KMT2AMEN1CKS1BSKP1 | |
| SCHEMBL24851167 | 0.89 | GBA1 (0.50) | GBA1KMT2AMEN1CKS1BSKP1 | |
| SCHEMBL18162447 | 0.89 | GBA1 (0.50) | GBA1KMT2AMEN1CKS1BSKP1 | |
| SCHEMBL30162196 | 0.89 | GBA1 (0.50) | GBA1KMT2AMEN1CKS1BSKP1 | |
| SCHEMBL24851770 | 0.88 | CKS1B (0.52) | GBA1KMT2AMEN1CKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199654-A1 | CTLA-4 SMALL MOLECULE DEGRADATION AGENT AND APPLICATION THEREOF | SUZHOU GUOKUANG PHARMTECH. CO., LTD. (CN) | 2024-06-20 | — | — | US | disclosed |
| EP-4310081-A1 | CTLA-4 SMALL MOLECULE DEGRADATION AGENT AND APPLICATION THEREOF | Suzhou Guokuang Pharmtech. Co., Ltd. (CN) | 2024-01-24 | — | — | EP | disclosed |
| EP-4310081-A1 | CTLA-4 SMALL MOLECULE DEGRADATION AGENT AND APPLICATION THEREOF | Suzhou Guokuang Pharmtech. Co., Ltd. (CN) | 2024-01-24 | — | — | EP | disclosed |
| CN-117157284-A | CTLA-4 small molecule degradation agent and application thereof | 苏州国匡医药科技有限公司 | 2023-12-01 | — | — | CN | disclosed |
| WO-2022194248-A1 | CTLA-4 SMALL MOLECULE DEGRADATION AGENT AND APPLICATION THEREOF | 苏州国匡医药科技有限公司 | 2022-09-22 | — | — | WO | disclosed |
| EP-3283472-B1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | UNIV INDIANA RES & TECH CORP (US) | 2021-04-14 | — | — | EP | disclosed |
| US-10273228-B2 | Hepatitis B viral assembly effectors | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180099952-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180099952-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-04-12 | — | — | US | disclosed |
| EP-3283472-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | Indiana University Research&Technology Corporation (US) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016168619-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016168619-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099952-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | HAVCR2, MAVS, HCCS | PIK3CA 3547/4885SMN1; SMN2 4578/4885USP2 1675/4885 |
| US-10273228-B2 | Hepatitis B viral assembly effectors | HAVCR2, MAVS, HCCS | PIK3CA 3547/4885SMN1; SMN2 4578/4885USP2 1675/4885 |
| US-20240199654-A1 | CTLA-4 SMALL MOLECULE DEGRADATION AGENT AND APPLICATION THEREOF | CD274, PDCD1, PDCD1LG2 | PIK3CA 1256/4885SMN1; SMN2 4393/4885USP2 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.